Seminars in Oncology

Papers
(The TQCC of Seminars in Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Unlocking the therapeutic potential of polyphenols: Promising advances and future directions in pancreatic cancer treatment40
Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance39
Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer28
Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review26
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis18
Editorial Board17
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics17
Military exposures and lung cancer in United States Veterans16
Role of neoadjuvant pembrolizumab in advanced melanoma15
Explainable machine learning and feature interpretation to predict survival outcomes in the treatment of lung cancer15
Global distribution of prophylactic total gastrectomy in E-cadherin (CDH1) mutations13
Advancing personalized medicine in LMICs: Predictive indicators for cervical cancer immunotherapy response12
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans12
Adenocarcinoma on retrorectal cystic hamartoma: An illustrative image for a very rare diagnosis12
Table of Contents12
Editorial Board12
Assessment of PSA responses and changes in the rate of tumor growth -rate with immune checkpoint inhibitors in US Veterans with prostate cancer11
Editorial Board11
Masthead10
The interest of therapeutic and pharmacological drug monitoring of methotrexate: A systematic review10
Breast cancer exosomes: Managing macrophage polarization and immune regulation in the tumor microenvironment9
Masthead9
Acute liver failure secondary to malignant infiltration: A single center experience9
The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward8
The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S.8
Biomarkers and the microbiome in the detection and treatment of early-stage non-small cell lung cancer8
Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)8
Editorial Board8
Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use8
Surgery for early-stage lung cancer with video-assisted thoracoscopic surgery versus open thoracotomy: A narrative review7
Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing—The experience of a large oncology center in t7
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population7
Screening Adherence for Second Primary Malignancies in Breast Cancer Survivors: Behaviors, Facilitators, and Barriers to Enhance Quality Care7
A narrative review of the principal glucocorticoids employed in cancer6
Hexokinases in gastrointestinal cancers: From molecular insights to therapeutic opportunities6
Recent updates on novel heterocyclic scaffolds of anticancer potential as emerging tubulin inhibitors6
Barriers and facilitators to lung cancer screening and follow-up6
Current and prospective antibody-based therapies in multiple myeloma6
Masthead6
Editorial Board5
Radiation recall dermatitis: A review of the literature5
Exosomal circular RNAs as drivers of temozolomide resistance in glioblastoma: Mechanisms and implications5
Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects5
High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy5
Colorectal cancer in Ethiopia: Epidemiological trends, diagnostic and laboratory capacities, and challenges5
Treating advanced lung cancer in older Veterans with comorbid conditions and frailty5
outside front cover5
Advances and challenges in cancer immunotherapy: Strategies for personalized treatment5
Masthead5
0.077855110168457